NEW YORK, April 18, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Lion Biotechnologies, Inc. (“Lion Biotechnologies” or the “Company”) (Nasdaq:LBIO) in the United States District Court for the Northern District of California on behalf of a class consisting of investors who purchased or otherwise acquired Lion Biotechnologies stock on the open market from November 14, 2013 and April 10, 2017, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) Lion Biotechnologies, through its former CEO Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion Biotechnologies on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than June 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 



